Cheryl Jorcyk, a member of Boise State’s Biomedical Research Center, recently published an article in conjunction with the National Center for Biotechnology Information titled “OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.”
The article characterizes the role of an inflammatory cytokine, oncostatin M (OSM), in the preintravasation aspects of breast cancer metastasis. Systemic and chronic inflammatory conditions in patients with breast cancer have been associated with reduced patient survival and increased breast cancer aggressiveness. Their findings suggest that early therapeutic inhibition of OSM in patients with breast cancer may prevent breast cancer metastasis.